MANNKIND CORP Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Amortized Cost
MANNKIND CORP (MNKD) had Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Amortized Cost of $170.96 million as of 2024-12-31, per its 10-Q filed 2025-08-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Held-to-Maturity, Maturity › Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date
us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis · last filed 2025-08-06
- 2024-12-31: Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Amortized Cost $170.96M.
- 2024-09-30: Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Amortized Cost $247.59M.
- 2024-06-30: Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Amortized Cost $244.73M.
- 2024-03-31: Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Amortized Cost $245.69M.
| Period end | Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Amortized Cost |
|---|---|
| 2024-12-31 | $170.96M 10-Q · filed 2025-08-06 |
| 2024-09-30 | $247.59M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $244.73M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $245.69M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $122.42M 10-K · filed 2025-02-26 |
| 2023-09-30 | $129.89M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $135.37M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $155.06M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $154.82M 10-K · filed 2024-02-27 |
| 2021-12-31 | $160.35M 10-K · filed 2023-02-23 |
| 2020-12-31 | $59.49M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |